PMID- 26558695
OWN - NLM
STAT- MEDLINE
DCOM- 20160602
LR  - 20220331
IS  - 1096-0384 (Electronic)
IS  - 0003-9861 (Linking)
VI  - 590
DP  - 2016 Jan 15
TI  - Histone deacetylase inhibitors reduce WB-F344 oval cell viability and migration 
      capability by suppressing AKT/mTOR signaling in vitro.
PG  - 1-9
LID - S0003-9861(15)30097-7 [pii]
LID - 10.1016/j.abb.2015.11.004 [doi]
AB  - Histone deacetylase (HDAC) can blockDNA replication and transcription and altered 
      HDAC expression was associated with tumorigenesis. This study investigated the 
      effects of HDAC inhibitors on hepatic oval cells and aimed to delineate the 
      underlying molecular events. Hepatic oval cells were treated with two different 
      HDAC inhibitors, suberoylanilidehydroxamic acid (SAHA) and trichostatin-A (TSA). 
      Cells were subjected to cell morphology, cell viability, cell cycle, and wound 
      healing assays. The expression of proteins related to both apoptosis and the cell 
      cycle, and proteins of the AKT/mammalian target of rapamycin (mTOR) signaling 
      pathway were analyzed by Western blot. The data showed that HDAC inhibitors 
      reduced oval cell viability and migration capability, and arrested oval cells at 
      the G0/G1 and S phases of the cell cycle, in a dose- and time-dependent manner. 
      HDAC inhibitors altered cell morphology and reduced oval cell viability, and 
      downregulated the expression of PCNA, cyclinD1, c-Myc and Bmi1 proteins, while 
      also suppressing AKT/mTOR and its downstream target activity. In conclusion, this 
      study demonstrates that HDAC inhibitors affect oval cells by suppressing AKT/mTOR 
      signaling.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China.
FAU - Zhu, Xiaofeng
AU  - Zhu X
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China.
FAU - Wu, Ying
AU  - Wu Y
AD  - Department of Biostatistics, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Hu, Ronglin
AU  - Hu R
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China.
FAU - Li, Dongming
AU  - Li D
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Du, Jun
AU  - Du J
AD  - Department of Microbial and Biochemical Pharmacy, School of Pharmaceutical 
      Sciences, Sun Yat-sen University, Guangzhou, Guangdong, China.
FAU - Jiao, Xingyuan
AU  - Jiao X
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China. Electronic address: jiaoxingyuan@hotmail.com.
FAU - He, Xiaoshun
AU  - He X
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China. Electronic address: gdtrc@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151110
PL  - United States
TA  - Arch Biochem Biophys
JT  - Archives of biochemistry and biophysics
JID - 0372430
RN  - 0 (Chromones)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Morpholines)
RN  - 31M2U1DVID (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one)
RN  - EC 2.7.1.1 (mTOR protein, rat)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.5.1.98 (Histone Deacetylases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects/physiology
MH  - Cell Line
MH  - Cell Movement/drug effects/physiology
MH  - Cell Survival/drug effects/*physiology
MH  - Chromones/administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Down-Regulation/drug effects/physiology
MH  - Hepatocytes/cytology/drug effects/*physiology
MH  - Histone Deacetylase Inhibitors/*administration & dosage
MH  - Histone Deacetylases/*metabolism
MH  - Male
MH  - Morpholines/administration & dosage
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Rats, Inbred F344
MH  - Signal Transduction/drug effects/physiology
MH  - Sirolimus/administration & dosage
MH  - TOR Serine-Threonine Kinases/*metabolism
MH  - Treatment Outcome
OTO - NOTNLM
OT  - AKT/mTOR signaling pathway
OT  - Apoptosis
OT  - Cell proliferation
OT  - Histone deacetylase inhibitor
OT  - Oval cells
OT  - Rapamycin
EDAT- 2015/11/13 06:00
MHDA- 2016/06/03 06:00
CRDT- 2015/11/13 06:00
PHST- 2015/03/25 00:00 [received]
PHST- 2015/11/03 00:00 [revised]
PHST- 2015/11/04 00:00 [accepted]
PHST- 2015/11/13 06:00 [entrez]
PHST- 2015/11/13 06:00 [pubmed]
PHST- 2016/06/03 06:00 [medline]
AID - S0003-9861(15)30097-7 [pii]
AID - 10.1016/j.abb.2015.11.004 [doi]
PST - ppublish
SO  - Arch Biochem Biophys. 2016 Jan 15;590:1-9. doi: 10.1016/j.abb.2015.11.004. Epub 
      2015 Nov 10.